Methods of use of anti-il-2 antibodies

Abstract

Described herein are therapeutic methods of use of engineered anti-IL-2 antibodies including dosages and administration regimes. The engineered antibodies may confer modified receptor binding specificity to an IL-2-anti-IL2 antibody complex, inhibiting the binding of IL-2 to CD25. The engineered anti-IL-2 antibodies may facilitate expansion of subsets of effector immune cells and decrease undesirable effects caused by IL-2. Therapeutic methods of use of the engineered anti-IL-2 antibodies includes treating cancer, for example treating cancers presenting as solid tumors and metastases thereof.

What is claimed is: 
     
         1 . A method of treating a solid cancer in a subject comprising a step of administering to the subject a composition comprising an anti-IL-2 antibody, said IL-2 antibody comprising a heavy chain variable region (VH) and a light chain variable region (VL), wherein said VH comprises heavy chain complementarity determining regions (HCDRs) HCDR1, HCDR2 and HCDR3, said VL comprises light chain complementarity determining regions (LCDRs) LCDR1, LCDR2 and LCDR3, wherein said CDRs have the amino acid sequences of
 HCDR1 comprises the amino acid sequence of SEQ ID NO:62, HCDR2 comprises the amino acid sequence of SEQ ID NO:63, HCDR3 comprises the amino acid sequence of SEQ ID NO:64, LCDR1 comprises the amino acid sequence of SEQ ID NO:65, LCDR2 comprises the amino acid sequence of DAS, and LCDR3 comprises the amino acid sequence of SEQ ID NO:67,   
       wherein the dose of said anti-IL-2 antibody is between about 0.5 mg/kg-12 mg/kg of said subject, and wherein said antibody promotes differential growth of subsets of immune cells and decreases undesirable effects caused by IL-2, thereby treating said cancer in said subject. 
     
     
         2 . The method of  claim 1 , wherein multiple doses of said composition comprising anti-IL2 antibody are administered. 
     
     
         3 . The method of  claim 1 , wherein said method further comprises administering at least a single low dose of IL-2, wherein said low dose of IL-2 comprises between about 15×10 3  IU/Kg-500×10 3  IU/Kg of said subject. 
     
     
         4 . The method of  claim 3 , wherein said administration of IL-2 comprises subcutaneous administration. 
     
     
         5 . The method of  claim 3 , wherein said IL-2 is administered prior to, concurrent with, or following the administration of said anti-IL-2 antibody. 
     
     
         6 . The method according to  claim 3 , wherein said IL-2 is administered as multiple doses. 
     
     
         7 . The method of  claim 6 , wherein said multiple doses of IL-2 are administered prior to, concurrent with, or following the administration of said anti-IL-2 antibody, or any combination thereof. 
     
     
         8 . The method of  claim 3 , wherein said method further comprises administering a checkpoint inhibitor. 
     
     
         9 . The method of  claim 8 , wherein said checkpoint comprises PD-L1, PD-1, CTLA-4, TIGIT, TIM-3, B7-H3, CD73, LAG3, CD27, CD70, 4-1BB, GITR, OX40, SIRP-alpha (CD47), CD39, ILDR2, VISTA, BTLA, or VTCN-1. 
     
     
         10 . The method according to  claim 1 , wherein said solid cancer comprises an unresectable locally advanced or metastatic cancer. 
     
     
         11 . The method according to  claim 10 , wherein said unresectable locally advanced or metastatic cancer comprises a melanoma, a renal cell carcinoma (RCC), a non-small cell lung cancer (NSCLC), a head and neck squamous cell carcinoma (HNSCC), gastric or gastro-esophageal cancer, esophageal squamous cell carcinoma, cutaneous squamous cell carcinoma (cSCC), pancreatic adenocarcinoma, cholangiocarcinoma (bile duct cancer), hepato-cellular carcinoma (HCC), colorectal cancer (CRC), epithelial ovarian cancer, cervical cancer, endometrial cancer, thyroid cancer having follicular or papillary histology, urothelial cancer, bladder cancer, uterine cancer, gallbladder cancer, or Merkel cell carcinoma. 
     
     
         12 . The method according to  claim 1 , wherein said solid cancer comprises a melanoma, a metastatic melanoma, a primary melanoma and metastatic melanoma, a renal cell carcinoma (RCC), a non-small cell lung cancer (NSCLC), a bladder cancer, a head and neck cancer, a head and neck squamous cell carcinoma (HNSCC), a nasopharyngeal carcinoma, a urothelial cancer, an adrenal cortical carcinoma, a clear cell renal cell carcinoma (ccRCC), a triple-negative breast cancer, a gastric or gastro-esophageal cancer, an esophageal squamous cell carcinoma, a cutaneous squamous cell carcinoma (cSCC), a pancreatic cancer, a pancreatic adenocarcinoma, a cholangiocarcinoma (bile duct cancer), a hepato-cellular carcinoma (HCC), a colorectal cancer (CRC), an epithelial ovarian cancer, a cervical cancer, an endometrial cancer, a thyroid cancer (follicular or papillary histology), a lung cancer, a uterine cancer, a gallbladder cancer, or a Merkel cell carcinoma, or any tumors that are microsatellite instabilities (MSI)-high tumors. 
     
     
         13 . The method according to  claim 1 , wherein said method comprises a first line treatment, a second line treatment, or a third line treatment, or a combination thereof. 
     
     
         14 . The method according to  claim 1 , wherein treating said subject reduces the size of the tumor, inhibits or reduces growth of the tumor, or inhibits or reduces metastases of said tumor, or any combination thereof. 
     
     
         15 . The method according to  claim 1 , wherein the VH and VL have the amino acid sequences of
 (a) the VH comprises the amino acid sequence of SEQ ID NO:26, the VL comprises the amino acid sequence of SEQ ID NO:27.   
     
     
         16 . The method according to  claim 1 , wherein the antibody comprises an IgG, IgA, IgM, IgE, IgD, a Fv, a scFv, a Fab, a F(ab′) 2 , a minibody, a diabody, or a triabody. 
     
     
         17 . The method according to  claim 1 , wherein said antibody comprises a heavy chain comprising a mutation that reduces binding to an Fcγ receptor. 
     
     
         18 . The method according to  claim 17 , wherein said mutation comprises L234A, L235A mutations. 
     
     
         19 . The method according to  claim 1 , wherein the amino acid sequence of the full length heavy chain is set forth in SEQ ID NO: 72 and the amino acid sequence of the full length light chain is set forth in SEQ ID NO: 73. 
     
     
         20 . A method of treating cancer in a subject comprising a step of administering to the subject an anti-IL-2 antibody and a IL-2, said IL-2 antibody comprising a heavy chain variable region (VH) and a light chain variable region (VL), wherein said VH comprises heavy chain complementarity determining regions (HCDRs) HCDR1, HCDR2 and HCDR3, said VL comprises light chain complementarity determining regions (LCDRs) LCDR1, LCDR2 and LCDR3, wherein said CDRs have the amino acid sequences of
 HCDR1 comprises the amino acid sequence of SEQ ID NO:62, HCDR2 comprises the amino acid sequence of SEQ ID NO:63, HCDR3 comprises the amino acid sequence of SEQ ID NO:64, LCDR1 comprises the amino acid sequence of SEQ ID NO:65, LCDR2 comprises the amino acid sequence of DAS, and LCDR3 comprises the amino acid sequence of SEQ ID NO:67,   
       wherein said IL-2 is administered by subcutaneous injection, wherein the dose of said anti-IL-2 antibody is between about 0.5 mg/kg-12 mg/kg of said subject, and wherein said antibody promotes differential growth of subsets of immune cells and decreases undesirable effects caused by IL-2, thereby treating said cancer in said subject. 
     
     
         21 . A method of treating solid cancer in a subject comprising a step of administering to the subject an anti-IL-2 antibody, an IL-2, and a checkpoint inhibitor, said IL-2 antibody comprising a heavy chain variable region (VH) and a light chain variable region (VL), wherein said VH comprises heavy chain complementarity determining regions (HCDRs) HCDR1, HCDR2 and HCDR3, said VL comprises light chain complementarity determining regions (LCDRs) LCDR1, LCDR2 and LCDR3, wherein said CDRs have the amino acid sequences of
 HCDR1 comprises the amino acid sequence of SEQ ID NO:62, HCDR2 comprises the amino acid sequence of SEQ ID NO:63, HCDR3 comprises the amino acid sequence of SEQ ID NO:64, LCDR1 comprises the amino acid sequence of SEQ ID NO:65, LCDR2 comprises the amino acid sequence of DAS, LCDR3 comprises the amino acid sequence of SEQ ID NO:67,   
       wherein said IL-2 is administered by subcutaneous injection, wherein the dose of said anti-IL-2 antibody is between about 0.5 mg/kg-12 mg/kg of said subject, wherein said antibody promotes differential growth of subsets of immune cells and decreases undesirable effects caused by IL-2, and wherein said checkpoint inhibitor comprises PD-L1, PD-1, CTLA-4, TIGIT, TIM-3, B7-H3, CD73, LAG3, CD27, CD70, 4-1BB, GITR, OX40, SIRP-alpha (CD47), CD39, ILDR2, VISTA, BTLA, or VTCN-1, thereby treating said cancer in said subject. 
     
     
         22 . The method according to  claim 21 , wherein said checkpoint inhibitor comprises a PD-L1 checkpoint inhibitor.